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Tämän työn tarkoituksena oli tutkia dexmedetomidiinin vaikutusta vastasyn-
tyneiden kortikaaliseen aktiivisuuteen analysoimalla tallennettuja aivosähkökäyriä
(EEG) tilastollisesti. Dexmedetomidiini on sedatiivi, joka on osoitettu tehokkaaksi
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jakaumaa ja multifraktaalisuutta. Dexmedetomidiinin havaittiin vaikuttavan sig-
naalien vaiheiden väliseen korrelaatioon sekä synkroniaan. Tämän lisäksi tässä
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Symbols
τ Time lag
j Imaginary unit
Pτ (a, b) Joint probability
θ(a, b) Phase difference
E Expected value
W Sum of ranked values
R Sum of ranks
Fq(s) Fluctuation function
Y (i) Signal profile
D(q) q-order singularity dimension
H(q) q-order Hurst exponent
h(q) q-order singularity exponent
σ Standard deviation
rs Spearman’s rho
∆ Delta values
Abbreviations
aEEG Amplitude-integrated Electroencephalography
ASI Activation Synchrony Index
BL Baseline epoch
CA Conceptional Age
cPSD Cross Power Spectral Density
DFA Detrending Fluctuation Analysis
DX Dexmedetomidine epoch
ECG Electrocardiogram
EDTF Energy-Weighted Temporal Dependency Function
EEG Electroencephalography
EOG Electrooculography
FFT Fast Fourier Transform
HIE Hypoxic-Ischemic Encephalopathy
IQR Interquartile Range
LI Lower 5th Index
MFDFA Multifractal Detrended Fluctuation Analysis
NICU Neonatal Intensive Care Unit
NC Nestedness Coefficient
PLI Phase Lag Index
PLV Phase Locking Value
PSD Power Spectral Density
rEEG Range-Electroencephalography
SAT Spontaneous Activity Transient
wPLI Weighted Phase Lag Index
1 Introduction
Neonatal intensive care unit is a place for infants suffering from various different com-
plications or disorders and in need of medical care. In intensive care, the infants are
often treated with drugs, frequently to provide sedation or analgesia. Dexmedeto-
midine has been previously used as a sedative with neonates. It is an agonist for
α2-adrenoreceptors in the central nervous system. Dexmedetomine’s advantages on
adults include minimal lowered respiration rate, sleep like induced sedation and has
short half-life of roughly from 1.5 to 3 hours, meaning that it is cleared from the
blood stream relatively fast. [1, 2, 3]
However, even though previously being used with infants and proven to be effec-
tive and safe with adults, the use of dexmedetomidine in Finland diminished after
concerns on the safety of dexmedetomidine on neonates were raised [4]. Although
it is possible that these concerns could be related to cardiovascular effects, such as
bradycardia, and not neurocognitive complications. [1, 2, 5] Studies of dexmedeto-
midine decreasing the blood flow in the brain on adults have been published and
thus, the effects of dexmedetomidine could also be seen in the cortical activity as
well [6].
The goal of this thesis is to study if the administration of dexmedetomidine to
babies would affect their brain activity. The dataset used in this thesis consisted
of electroencephalographic recordings of 22 neonates, both preterm and fullterm.
However, only recordings from 21 subjects were analyzed as one subject was rejected
due to having a recording only after receiving the drug. Most subjects had recordings
taken both before and after the subjects received the drug and most of them had
a duration of roughly four hours (8 hours in total per baby). By examining the
effects, it is also hoped to shed light on whether the dexmedetomidine would be
safe to use in neonates. The recordings contained four channels and the studied
frequency bands ranged from 0.2 to 35 Hz. A total of eight different computational
features were selected to quantify the data and to be statistically analyzed. These
features were selected based on Julia Jaatela’s previous work and other literature
as well as on advice from a medical doctor [7]. This thesis consists of two different
studies for determining:
1. What are the hour-long effects of dexmedetomidine?
2. What are the short-term effects seen immediately after the dosing?
Julia Jaatela’s thesis, titled "Computational features of neonatal EEG monitoring
after asphyxia", was used as a baseline and roughly followed for the applicable parts
when carrying out the studies for this thesis.
For determining the hour-long effects of dexmedetomidine, as much as possible of
all the recordings were used to plot time-trends of the eight different computational
features. The time-trends consisted of all of the subjects plotted in the same figure
together with a mean value. These time trends were then visually analyzed to
determine any changes in the cortical activity.
2The second study for determining the short-term effects consisted of two differ-
ent statistical analyses. For this study a 12-minute baseline epoch just before the
drug administration and a 10-minute epoch after the drug were extracted. The first
statistical analysis then had the feature values of these epochs compared to deter-
mine if there were any differences between them. For the second statistical analysis
we subtracted the baseline value from the postdrug value and studied whether the
change correlated with the baseline value. The second analysis was included as we
suspected that the background state of the subject might affect the postdrug feature
values.
Finally, other clinical factors besides dexmedetomidine affecting the selected fea-
tures were examined. The clinical factors were administration of fentanyl, con-
ceptional age and background diagnosis. These factors were compared against the
baseline values of the features and analyzed for correlations.
32 Background
The aim of this section is to introduce the background of the study field regarding
this thesis. In this section we first take a look on EEG on a basic level. After this, the
differences between neonatal EEG and the EEG of an adult are discussed. Together
with the neonatal EEG, the neonatal intensive care unit (NICU) is introduced as it
is the environment where the subjects were treated and the EEG recordings carried
out. For the subjects to be critically ill and treated at NICU is an essential part of
the study. Finally, EEG analysis and monitoring is discussed.
2.1 Electroencephalography
The brain of an adult consists of up to a 1011 neurons and even a greater amount
of other type of cells, such as various glial cells, that make up a major part of the
volume of the brain [8]. The neurons process information and communicate with
electrical signals that are passed through junctions, called synapses, that connect
two separate neurons. EEG is a method for studying this electrical activity of the
cerebral cortex, that is the outer layer of brain. However, as the potentials of a
single neuron or synapse are too weak to be detected by EEG, the detected brain
waves consist of potentials that are a sum of a larger population of postsynaptic
action potentials [9].
The electrical activity recorded in EEG is the potential difference between two
distinct areas on the scalp. This potential difference can be either between two elec-
trodes or every electrode in respective to an common reference. The recorded activ-
ity is conventionally divided into four different frequency bands, delta (0.5–4 Hz),
theta (4–8 Hz), alpha (8–13 Hz) and beta (13–30 Hz) [10]. In adults, delta waves
are present during deep sleep. However, they are also normal in awake neonates.
Theta waves are typically found during emotional stress but are also common in
many disorders of the brain. Alpha waves are normally found in EEGs of adults
who are awake and resting, while beta waves are occur when the nervous system is
activated. [8]
Traditionally EEG is noninvasive and voltage sensitive electrodes are placed on
top of the scalp. The number of electrodes used for recording the brain activity
can vary depending on the situation, however, their placement usually follows an
international 10–20 system [11]. The placement of electrodes is determined with the
help of anatomic landmarks found in the skull to accommodate for the differences
in head sizes and shapes [12]. In this system, every electrode position is designated
with a name that comprises of a letter and a number. The letters determine the
region that the electrode is located in, F for frontal, T for temporal, P for parietal
and O for occipital lobes. In addition, a letter C is also used and stands for central.
The numbers are assigned based on the hemisphere, even for right and odd for left
hemisphere. Thus, every electrode position has a unique identifier. The electrode
placement is illustrated in Figure 1. For practical reasons, such as the small head
size, the EEG of neonates is often recorded with only a few electrodes per hemisphere
following the international 10–20 system.

52.2 Neonatal EEG and intensive care unit
The development of the nervous systems starts already in the early weeks of gestation
with the differentiation of nervous cells and can be considered to continue throughout
the lifespan [19]. During the early development of the brain, cortical activity and
sensory inputs play critical roles resulting in modifications of the brain. These
modifications take place via branching of axons, controlled cell death as well as
through the addition, removal and stabilization of synapses [20]
Due to the development of the brain, the neonatal cortical activity that can be
recorded with EEG possesses unique features. Most importantly, the background
state of EEG recorded from a neonatal brain differs significantly from adult one.
One of the common distinguishing aspects of preterm EEG, babies born before age
of 37 weeks, is the discontinuity compared to the EEG of an adult. Thus the preterm
EEG is normally categorized into either being continuous or discontinuous. With
preterm infants intermittent burst of activity are common in presence of otherwise
discontinuous EEG [21]. These bursts of activity are called spontaneous activity
transients (SATs) [22]. These are thought to originate from the subplate zone of
neonatal brain, which is located underneath the cortical layer. The cortical sub-
plate zone is also considered to regulate the cortical activity of preterm infants over
cortical connections [23]. As the infant matures, the EEG becomes more and more
continuous and the SATs disappear together with the subplate as the infant reaches
term age [24]. The activity of a full-term infant is continuous during both, wake-
fulness and active sleep [21]. SATs are considered to correspond to the brain wiring
itself [24].
Another difference between the cortical activity of preterm infants and adults
is the expression of sleep stages. As described earlier the EEG of preterms with
conceptional age (CA) below 32 weeks is discontinuous and the waking and sleeping
states cannot be distinguished from each other. After an age of 32 weeks CA, a
differentiation between active sleep, quiet sleep and wakefulness begins. However, it
is only after 36 weeks CA when these states can be correlated with three different
EEG patterns. [21] The quiet sleep is characterized with discontinuity while active
sleep is continuous. [25]
NICU is a place for treating and monitoring critically ill neonates in need of
special treatment. Reasons behind the neonate requiring intensive care include
premature birth, difficulties in breathing, infections or birth defects, neurological
disorders, labor complications or problems caused by the mother’s disease. [26]
As the neonates are critically ill, they are often treated with drugs, such as seda-
tives. The drug of interest in this thesis, dexmedetomidine, is one example of these
sedatives. One common reason for a neonate to be administered dexmedetomidine
has been hypoxic-ischemic encephalopathy (HIE), which is brain damage caused by
asphyxia, the lack of oxygen in the brain. The standard treatment for moderate
or severe HIE is lowering the body treatment of the neonate down to 33-34◦C for
72 hours, after which the body temperature is raised slowly back to normal [27].
Preceding the hypothermia treatment, the neonates often need to be sedated to
lessen the stress and the tremor of the baby. Although the cardiovascular effects of
6dexmedetomidine in neonates are known, the neurocognitive effects have not been
studied extensively and remain unclear [28, 29]. Generally, concerns of anesthetics
being linked to inducing apoptosis in the developing brain have been raised in recent
years, especially during general anesthesia [30, 31, 32].
It has been stated that conditions associated with prematurity and also treatment
during the infants stay at NICU may account for the subsequent neurocognitive
conditions or outcomes [22]. This could be due to the timing of when the preterm
babies are admitted to NICU often roughly corresponding to the third trimester of
the pregnancy, which is the period when the growth of long-range connections in
brain occurs.
2.3 EEG analysis and monitoring
EEG is a powerful tool for both studying and monitoring the brain activity of
neonates. Common fields of interest in EEG studies include the study of drug
effects, where EEG is statistically analyzed for tracing drug-induced and time-related
changes in the frequency and amplitude of EEG signals. In studies of this kind, EEG
is recorded both before and after the drug dosing. This way the EEG after the dosage
can be statistically compared to the baseline EEG (before the dosage). Commonly
EEG is used to study the drug effects both spatially as well as temporally. Despite
the poor spatial resolution, EEG can be used to, at minimum, determine if the
drug-induced changes are restricted to either hemisphere of the brain. [33]
In computational EEG analysis the data is often described with specific com-
putational features. In essence, these features are quantitative parameters used for
extracting information that might not be possible to see or quantify visually. Some
computational features for analyzing neonatal brain activity have been adopted from
the ones used for adults, however, metrics have also been developed and tailored for
neonatal EEG directly. In EEG analysis, the focus is usually in the main compo-
nents of EEG: amplitude, frequency and phase [34]. Often in EEG analysis the
discrete values used for representing the data are found to have interdependencies
such as covariances or correlations. Thus for instance, analyzing the degree of syn-
chrony between two signals that originate from different spatial location of the brain
is common.
EEG monitoring, especially amplitude-integrated EEG (aEEG), is often used
for observing the cerebral activity of neonates in intensive care. As the background
activity of EEG can be used to predict the outcome of both term asphyxiated infants
and preterm infants. In addition, aEEG is a powerful tool in detecting seizures and
can also be used to monitor responses to drug therapy and depth of anesthesia
[35, 36, 33]. EEG has been shown to be sensitive towards being modulated by
various drugs. Examples of drug effects on EEG activity include: increase of power in
specific frequency bands, depression of background activity and obscuring sleep-wake
cycles.[22, 33, 37] However, aEEG should be used as a complement to normal EEG
when possible, and due to its unique nature, successful EEG monitoring requires
collaboration between neonatologists and clinical neurophysiologists [36].


93.2 Data pre-processing
After visual analysis, most recordings were found to contain artifacts that had to
be removed before other pre-processing could take place. However, this was to be
expected as clinical data was used and it almost always contains artifacts. If the
artifacts were not removed, they could affect the data in undesired ways and reduce
the quality of the data. For example, high amplitude peaks caused by artifacts could
lead to ringing when the signals are filtered. Thus, an artifact detection system was
developed for detecting different types of artifacts. The principle of this system was
that it most importantly removed all high amplitude artifacts, as well as marked
the signal for lower amplitude artifacts that could alter the results of the research
later on.
After the high amplitude artifacts were removed, the DC component was then
removed from the signals by computing the mean from the whole length of the
recording and then subtracting the mean value from the signal. The signals were
then band-pass filtered. The band-pass filtering was carried out with separate fifth
order Butterworth high-pass and a seventh order Butterworth low-pass filters with
cutoff frequencies of 0.2 Hz and 35 Hz, respectively. The signals were filtered in both
forward and reverse directions to avoid phase shifting. Finally, the the recordings of
the two subjects with sampling frequency of 500 Hz were down sampled to 250 Hz.
3.2.1 Artifact detection
The artifact detection algorithm consisted of three separate detectors, amplitude-
based as well as a high frequency and low frequency artifact detectors. The amplitude-
based detector had a threshold of 500 µV for the maximum of EEG, above which
the signal was assumed to contain an artifact. Moreover, when a peak exceeding
500 µV was found, the threshold was lowered to 300 µV for 7 seconds around the
artifact. This was done to detect the "secondary" artifacts and ringing caused by
the large artifact.
For both the low and high frequency artifact detectors, the signals were cut down
in to 2.5 min epochs, after which Welch’s power spectral density was calculated for
all of the epochs. The frequency bands for the low and high frequency artifacts
were chosen to be 0.15–0.5 Hz and 15–25 Hz, respectively. The powers transferred
over these bands were then normalized by dividing them with the power transferred
over a frequency band from 1 Hz to 10 Hz and plotted in histograms. This was
done to visualize the distribution of the power transferred in these epochs and the
frequency bands in question. As the power spectral density distributions were found
to follow normal distribution, outlier epochs were assumed to contain artifacts. For
the assumption, 95 percentile was chosen to be the threshold and epochs with higher
values were considered as outliers. These assumptions were verified after visually
analyzing the validity of the artifact detectors. The normalized high frequency power
spectral densities of each epoch can be found in Figure 4.
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Table 1: Summary of the computational features used in all of the studies conducted.
Table presents the feature names, types, montages and frequency bands. The last column
presents the number of different variables obtained for each feature.
Feature Type Montages Frequency bands (Hz) Number of variables
ASI Interhemispheric synchrony
F3P3—F4P4
F3—P3
F4—P4
F3—F4
P3—P4
1.5—20 5
wPLI Phase-phase synchrony
F3—P3
F4—P4
F3—F4
P3—P4
0.25—3, 3—8, 8—15 and 15—30 16
NC Phase-amplitude synchrony
F3
F4
P3
P4
3—8, 8—15 and 15—30 12
PSD Spectral density
F3P3
F4P4
F3F4
P3P4
F3
F4
P3
P4
1—3, 3—8, 8—15 and 15—30 32
cPSD Spectral density
F3P3—F4P4
F3—P3
F4—P4
F3—F4
P3—P4
1—3, 3—8, 8—15 and 15—30 20
aEEG Peak-to-peak amplitude
F3P3
F4P4
F3F4
P3P4
F3
F4
P3
P4
2—15 16
rEEG Peak-to-peak amplitude
F3P3
F4P4
F3F4
P3P4
F3
F4
P3
P4
0.5—35 24
MFDFA Multifractality
F3P3
F4P4
F3F4
P3P4
F3
F4
P3
P4
0.2—35 32
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3.3.1 Activation synchrony index
Activation synchrony index (ASI) quantifies the co-occurrence of SATs between two
EEG signals. It was developed by Räsänen et al. [38] as an objective measure
to quantify the interhemispheric synchrony. Interhemispheric synchrony is one of
the key features when analyzing the background activity of neonatal EEG. This
interaction of the hemispheres has been shown to increase with age of the neonate,
and on the other hand, decrease with different disorders in the brain. ASI is based
on computing statistically the time delay between quantized amplitude envelopes of
two EEG signals [38].
Following the work of Räsänen et al. [38] the signals were first pre-processed.
The pre-processing consisted several steps, first of which was the down-sampling the
signals to 50 Hz from 250 Hz. In addition, a finite impulse response high-pass filter
of first order was used to emphasize higher frequencies that are related to SATs.
After filtering, the amplitude envelopes of the two signals were then computed with
the use of fast Fourier transformation (FTT). The FTT used a sliding Hamming
window with a 100 ms step size. The width of the Hamming window was 2 seconds.
After FFT the amplitudes of frequency bins corresponding to a range from 1.5 Hz
to 20 Hz were summed up.
Next step in the pre-processing of ASI was the quantization the envelopes into
Q discrete levels. A random subset of samples was clustered with standard k-means
algorithm, after which every sample was assigned to the closest resulting cluster.
This resulted in two sequences that are discrete and correspond to the two input
signals A and B. The purpose of quantization of the envelopes is to be able to
represent the two signals with a small enough number of levels that allow reliable
estimation of joint probabilities of amplitude value combinations between these two
signals. This is due to the joint probability space increasing exponentially with the
number of quantization levels [38]. The chosen number of quantization levels in this
study was 8, based on the previous work of both Räsänen et al. [38] and Koolen et
al. [39].
After pre-processing, the next step was to measure the dependency of the com-
puted signal states. The dependency was measured by calculating an energy-weighted
temporal dependency function (EDTF) between the quantized envelopes. EDTF
measures the statistical dependencies of all signal state pairs with different tem-
poral delays. In order to measure the dependency of signal energy, as opposed to
states, every state pair is weighted with the product of the amplitude values of the
associated states. EDTF can be expressed as the following equation:
EDTF(τ) =
∑
a,b
E(a)E(b)
Pτ (a, b)
2
P (a)P (b)
, (1)
where Pτ (a, b) is the joint probability for observing levels a and b in signals A and
B respectively, when signal B is delayed by τ . P (a) and P (b) are the individual
probabilities for observing these levels. The time delay of τ had a range from −5
to +5 seconds. E(a) and E(b) denote the amplitudes corresponding to quantization
levels a and b.
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For measuring the relative EDTF values at different lags, EDTFs global minimum
was subtracted from all EDTF values. The final ASI value was then calculated as a
ratio of the EDTF value at τ = 0 divided by the mean EDTF over the entire range
of −5 to +5 s:
ASI = EDTFnorm(τ = 0)
/( 1
length(τ)
5s∑
τ=−5s
EDTFnorm(τ)
)
, (2)
where EDTFnorm(τ) is the relative EDTF value. This ratio, which is obtained with
Equation 2, describes the magnitude of coupling between the signals A and B with-
out any delay compared to the coupling with delay.
In this thesis ASI was measured between the two hemispheres, F3P3–F4P4,
as well as between the monopolar channels, F3–P3, F4–P4, F3–F4, P3–P4. This
resulted in five different ASI values for every epoch.
3.3.2 Weighted phase lag index
Phase-locking or phase synchrony is the correlation between the phases of two sig-
nals. It means that the phase difference between these signals stays fixed, over a
certain period of time. This is illustrated in Figure 6. Phase synchrony is regarded
as the functional interaction between two distinct areas of the brain [40]. There
are different methods for quantifying the phase synchrony, such as phase locking
value (PLV). PLV uses the phases of signals to estimate their phase covariance. The
following equation is used for computing PLV:
PLV =
1
N
∣∣∣∣∣
N∑
n=1
exp(jθ(t, n))
∣∣∣∣∣ , (3)
where N is the number of samples, j is imaginary unit and θ(t, n) is the phase
difference between the two signals.
It was first introduced by Lachaux et al. [42]. However, PLV has several dis-
advantages, such as volume conduction, noise and use of common reference. Thus
a new measure, called phase lag index (PLI), was developed by Stam et al. [43].
PLI uses the imaginary component of cross-spectrum to estimate phase correlation.
Although PLI is less sensitive to volume conduction than PLV, noise still poses a
problem for PLI [43]. To further improve PLI’s robustness towards volume con-
duction and noise, Vinck et al. [44] introduced weighted phase lag index (wPLI)
in 2011. wPLI weights the PLI by the magnitude of its imaginary component. If
the phase difference between the two signals is close to either 0◦ or 180◦, noise can
rotate the cross-spectra across the real axis, turning phase lags to leads and vice
versa. However, as the imaginary component of the cross-spectrum is 0 with phase
differences of 0◦ and 180◦, the weighting makes wPLI less sensitive to noise than
PLI. The difference between PLI and weighted PLI is illustrated in Figure 7. To
overcome the problem of sample-size bias, Vinck et al.[44] proposed a metric called
debiased wPLI.
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The first step when computing debiased wPLI is the computation of imaginary
components of the cross-spectrum. After the imaginary components have been com-
puted, they are averaged to one value. The computed average is then normalized by
the magnitudes of the imaginary components. This results in a following equation:
wPLI =
∑N
j=1
∑
k=j+1Wj,kd(Xj, Xk)
N(N − 1)W
, (4)
where Wj,k ≡ |=(Xj)=(Xk)| is the weight, d(Xj, Xk) ≡ sign(=(Xj))sign(=(Xk)),
W is the normalized weight and =(X) is the imaginary component of the cross-
spectrum of the respective signal. [44] The wPLI was computed for frequency bands
of 0.25–3 Hz, 3–8 Hz, 8–15 Hz and 15–30 Hz and between monopolar channel pairs of
F3–P3, F4–P4, F3–F4 and P3–P4. Thus, the total number of wPLI values obtained
for every epoch was 16.
3.3.3 Nestedness coefficient
Endogenous burst have been shown to often occur during slow and large voltage
deflections in neonatal brain [45]. Nestedness coefficient (NC) is a measure used
for estimating this coupling between the phase of slow oscillations and amplitude of
faster oscillations within a signal. In other words, this means that the amplitude of
the fast oscillations is modulated by the phase of the slow oscillations [46]. Alter-
natively, the slow oscillation can be phase-locked to the amplitude peaks of the fast
oscillations [47]. These nested oscillations have been shown to exist across multiple
frequency bands, and possibly play a crucial role in the regulation of large-scale neu-
ronal activities, such as the execution of cognitive functions [45, 46, 48]. In addition,
nested oscillations correlate with sensory awareness [49].
In this study the slow oscillations were considered to have a frequency band
from 0.2 Hz to 0.6 Hz. The faster oscillations were divided into three frequency
bands: 3–8 Hz, 8–15 Hz and 15–30 Hz. For extracting the different frequency bands
from the signal, a pair of low-pass and high-pass FIR filters were applied in both
forward and backward directions. After filtering, an amplitude envelope for the
higher frequency component was obtained with calculating the complex magnitude
of Hilbert transformed signal in question. This envelope was afterwards filtered
with the same low-pass and high-pass filters used for the lower component. Both
the amplitude envelope and the lower component were then extended into complex
plane with Hilbert transform. The last step in calculating NC was the computation
of PLV, as shown in Equation 3, between these complex signals. In other words, NC
thus estimates the phase correlation between the slow oscillating component of the
signal and the amplitude envelope of the faster oscillation. Phase-amplitude coupling
is illustrated in Figure 8. NC was computed within every monopolar channel and
with the three frequency bands, resulted in a total of 12 values for every epoch.
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3.3.4 Power spectral density
In power spectral density (PSD) analysis the power of the signal is plotted against
frequency. Thus, PSD describes how the power is distributed into different frequen-
cies. Attenuation of EEG can be detected with PSD and it has been shown to differ
between healthy and sick neonates in a low frequency range close to delta waves
[50].
In the studies, Welch’s estimate was used to compute the PSD. In this method,
the time series is divided into segments, which was chosen to be 10 seconds in length
with 50% overlap. After the division into segments, a Hamming window is applied
before obtaining modified periodograms from each segment. The periodograms are
obtained by computing the fast fourier transforms (FFTs) of autocorrelation func-
tions of the segments. These periodograms are then averaged to reduce variance
and an estimate of PSD for the time series is obtained. [51]
A total of four frequency bands were used, specified in Table 1, for which the
average power carried over the frequency band were estimated. Averaging was done
by taking a mean value of the spectrum to obtain a single value of power per fre-
quency band. An example of a modified periodogram computed from one 5 min
long epoch, two subsequent 2.5 min epochs, of one subject can be seen in Figure 9.
Figure 9: Power spectral density of computed from 5 min epoch of one of the subjects.
The original signal is shown above the PSD.
3.3.5 Cross power spectral density
Cross power spectral density (cPSD) is often used in computing the coherence of
two signals, which is a measure used to evaluate phase correlation, as is wPLI [41].
However, in our studies we used cPSD to measure the powers of two channels. While
PSD estimates the signal power of one channel, cPSD assesses the power per unit
frequency shared between two channels.
The computation of cPSD is similiar to the one of PSD with the exception that
cross-correlation is used instead of autocorrelation. Thus, cPSD is the FFT of the
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cross-correlation of the two signals. Cross-correlation of two signals X1 and X2 can
be defined as:
RX1,X2(τ) = E[X1(t)X2(t+ τ)], (5)
where τ is the time lag between the two signals. To estimate the cross power spectral
densities Welch’s estimate was used in the same manner as with PSD. cPSD was
computed for the same montage pairs as ASI, as it also is a measure between montage
pairs. With the four frequency bands (1–3 Hz, 3–8 Hz, 8–15 Hz and 15–30 Hz), it
resulted in 20 different values for every epoch.
3.3.6 Amplitude-integrated EEG
Amplitude-integrated EEG (aEEG) is used for bedside monitoring of neonates for
seizure detection and evaluation of the baseline activity of the brain [52]. aEEG can
additionally be used for predicting the outcomes of neonates with encephalopathy
caused by various reasons [53]. In aEEG the raw EEG recording is first filtered so
that frequencies below 2 Hz and above 15 Hz are attenuated strongly. After filtering,
the signal is then rectified and smoothed to illustrate the trending. Thus, aEEG is a
measure of peak-to-peak amplitude. aEEG is presented in a time-compressed form
to illustrate the activity of the brain over longer time periods. [54]
After the computation, two attributes of aEEG were then calculated. These
attributes were mean and interquartile range (IQR). These two attributes charac-
terize the different aspects of the value distributions, mean is associated with the
central tendency while IQR describes the spread or variability of the distribution
[54]. Both of these can be used to analyze the possible attenuation of EEG caused
by dexmedetomidine. The appereance of aEEG is illustrated in Figure 10.
Figure 10: An example of aEEG from one of the subjects. The figure shows one channel
of a postdrug recording that has been transformed into aEEG.
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3.3.7 Range-EEG
In order to account for the filtering in aEEG and thus underestimation of frequencies
either below 2 Hz or over 15 Hz, range-EEG (rEEG) can be used to measure the
peak-to-peak amplitudes of EEG. rEEG is calculated as the minimum amplitude
substracted from the maximum amplitude for two second windows with no overlap.
This corresponds to the high-pass filtering of 0.5 Hz of traditional EEG. [54] On
the contrary to aEEG, which is an underestimate of peak-to-peak amplitude, rEEG
is an overestimate. This means that the value of rEEG is a little higher than the
average peak-to-peak amplitude for a two second window.
The rEEG recordings were cut into 2.5 min epochs without overlap and three
different variables were then computed for each epoch. These variables were mean,
IQR and lower 5th percentile (LI). LI of rEEG has been proven to increase with
the maturation of the brain and its abrupt rises has been associated with epileptic
seizures [54, 36]. The appereance of rEEG is illustrated in Figure 11.
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Figure 11: An example of rEEG from one of the subjects. The figure shows the same
channel of a postdrug recording transformed into rEEG as with aEEG.
3.3.8 Multifractal detrended fluctuation analysis
Structures or patterns repeating itself over various temporal scales are often found
in biomedical signals [55]. One method to assess this self-similarity or fractality is by
detrending fluctuation analysis (DFA). If the fractality of the signal is temporally and
spatially independent, the structure can be defined by a single singularity exponent
and is considered monofractal. However, if a single exponent is not sufficient to
express the power-law of the fractality and several are needed, the signal is considered
multifractal. DFA has been adapted to multifractal signals, resulting in a method
called multifractal detrended fluctuation analysis (MFDFA).
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Multifractal analysis has not only been shown to differentiate between different
pathological conditions but also between the neural activity of different areas of
the brain [56, 57]. Thus, multifractal analysis could serve as a powerful tool in
diagnostics.
The computation of MFDFA consisted of five steps, following the work of Kanel-
hardt et al. [58]. The first step was determining the profile of the signal. This
means that the noise like signal is converted into random walk by first subtracting
the mean value the signal followed by integration of the time series. This is done in
the following equation:
Y (i) ≡
N∑
n=1
(xn − 〈x〉), i = 1, ..., N. (6)
In this equation N is the number of data points and 〈x〉 is the mean of the signal.
In the second step, the profile Y (i) was divided into Ns segments with no overlap
and a length of s data points. After the division into segments, local trends for
each segments were computed with the usage of a least-square fit. The third step
also included determining the variance for each segment v with a length of s by the
following equation:
F 2(s, v) ≡
1
s
s∑
i=1
Y [(v − 1)s+ i]− yv(i)
2
, v = 1, ..., Ns. (7)
The fourth step consisted of averaging over all segment in order to obtain the fluc-
tuation function of qth order. The values for index q used in this thesis had a range
from −5 to +5 with a step size of 0.5, following the work of Matic et al. [59].
Fq(s) ≡
1
Ns
Ns∑
v=1
(
[F 2(s, v)]q/2
)1/q
. (8)
The second, third and fourth steps are repeated for different segment lengths in
order to assess the dependence between fluctuation functions Fq(s) and time scales.
The time scales of s used in this work had a range from 25 to 1875 samples, 1875
samples fitting twenty times into a 2.5 min epoch with a sampling frequency of
250 Hz. The smallest scale of 25 samples was determined, following the instructions
found in the work of Ihlen at al. [55]. The number of scales in total was 19 and
they were determined by equidistant spacing in logarithmic scale between log2(25)
and log2(1875).
The fifth and final step was to determine the scaling behaviour of the fluctuation
functions Fq(s). The relation between the fluctuation functions and scales is shown
in the following equation:
Fq(s) ∼ s
H(q). (9)
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The scaling behaviour was determined by analyzing plots of Fq(s) against differ-
ent scales of s in logarithmic scale with different values of q. An example of these
plots is shown in Figure 12. The slopes of these plots are q-order Hurst exponents,
H(q). The q-order Hurst exponents can be used to determine both the q-order
singularity exponent h(q), as well as the q-order singularity dimension D(q):
h(q) = H(q) + qH ′(q) and D(q) = q[h(q)−H(q)] + 1. (10)
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Figure 12: An example of q-order fluctuation F (q) plotted against different scales of s in
logarithmic scale. Different values of q are plotted in their own lines, of which slope is the
respective q-order Hurst exponent.
A multifractal spectrum can be obtained by plotting the D(q) against the sin-
gularity strength h(q). An example of multifractal spectrum is shown in Figure
13. Out of the multifractal spectrum, four variables were extracted that describe
the spectrum. These variables were width hq, height Dq, peak hq and tail Dq.
While the two first measures are related to the size of the spectrum, peak hq and
tail Dq describe the asymmetry of the spectrum. Both width hq and height Dq
were computed following work of Zorick and Mandelkern [60]. Width hq is the
difference between the maximum and minimum h(q) values. Height Dq describes
the temporal changes in the local Hurst exponents and is defined as the minimum
D(q) subtracted from the maximum D(q). Peak hq is the singularity exponent
h(q) where the singularity dimension D(q) reaches its maximum. The last variable,
tail Dq, describes whether the multifractal spectrum has a longer tail either with
smaller or larger values of h(q). A left tail refers to a longer tail with smaller values
of h(q) (negative tail Dq), while right tail stands for a longer tail with larger values
(positive tail Dq).
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From the test statistic, a z-score can then be calculated as:
z =
W
σW
, σW =
√
N(N + 1)(2N + 1)
6
, (11)
where σW is the standard deviation of W and N the number of pairs.
This z-score is then compared to a z-distribution, in order to obtain a p-value for
the test. The null hypothesis for Wilcoxon signed-rank test is that the differences
of the two samples follow a distribution, which has a median of zero. The tests p-
value is the probability of observing a value greater than or equal to the calculated
test statistic. [62] Based on the p-value and a chosen level of confidence, the null
hypothesis either holds or is rejected. In the statistical analyses performed in this
thesis, the chosen confidence level was 0.05 and p-values less than or equal to 0.05
meant the rejection of the null hypothesis.
3.4.2 Wilcoxon rank-sum test
Wilcoxon rank-sum test was used when the observations were not paired. It is
a statistical method for testing the equality of medians between two groups. In
Wilcoxon rank sum test, the two groups of samples are merged together and every
sample is assigned a rank based on its magnitude. Unlike in the signed-rank test,
only positive ranks are assigned and the sign of the sample is neglected. A test
statistic W is then calculated as the sum of ranks of the first group. With large
enough sample sizes, a z-statistic can then be used to compute the p-value of the
test. The z-statistic in Wilcoxon rank-sum is defined as:
z =
W − E(W )
σW
, (12)
where E(W ) is the expected value of the test statistic W and σW is its standard
deviation.
As with the Wilcoxon signed-rank test, the Z-statistic is then compared to z-
distribution for obtaining an approximation of the p-value. The selected level of
significance was 0.05 in all of the Wilcoxon rank-sum tests. [61, 62]
3.4.3 Kruskal-Wallis test
Kruskal-Wallis tests the null hypothesis that all the values of different groups come
from the same distribution. An often used method for the same problem is the F-
test that assumes that all the distributions are normally divided, however, no such
assumption is made with Kruskal-Wallis. It can be used for three or more groups
and the sizes of the groups do not have to be equal. [63]
In Kruskal-Wallis, null hypothesis is tested by ranking the samples of all the
groups from 1 to N and calculating H statistics. By using the ranks instead of
actual values, the calculations are simplified and only general assumptions, such as
symmetry of the distribution and independence of the samples, are made.
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If two or more observation have the same value, they are replaced by the mean of
their supposed rankings. H-test is defined by:
H =
12
N(N + 1)
C∑
i=1
R2i
ni
− 3(N + 1), (13)
where C is the number of groups, N is the number of observation in all C groups
combined and Ri is the sum of the ranks in a group i.
For large enough number of observations, value H is then compared with the
χ2-distribution, which is the sum of squared errors with the degree of freedom being
the number of groups, C. If H is larger than χ2(C − 1), the null hypothesis is
rejected. Kruskal-Wallis is one-way variance analysis and it compares the medians
between each group. This test does not tell which two groups differ significantly,
only that some of them do or none of them do not.
3.4.4 Spearman’s rank correlation
Spearman’s rank correlation is a nonparametric measure for the dependence of the
ranks of two samples. When computing Spearman’s rho, the two samples are first
ranked separately based on their magnitude while keeping the observation pairs
intact. Pearson’s correlation coefficient is then calculated for these n pairs of ranks.
[62] Spearman’s rho is defined as:
rs =
∑n
i=1(xi − x)(yi − y)
σxσy
, (14)
where xi and yi are the ranks of the i
th pair of observations. Moreover, x and y are
the means of ranks of the two samples. σx and σy represent the standard deviations
of the two ranked samples and n is the number of pairs.
If there are no ties between the ranks in the samples, Spearman’s rho can be
simplified to:
rs = 1−
6
∑n
i=1D
2
i
n(n2 − 1)
, (15)
where Di is the difference between the ranks of the i
th pair, Di = xi − yi. [62]
As Spearman’s rank correlation is calculated with ranks instead of actual values
of the observations, it is more resistant towards outliers than Pearson’s correlation.
The correlation coefficient gets values between −1 and +1, so that −1 equals perfect
negative correlation, 0 means no correlation and +1 is perfect positive correlation.
Although, a correlation could be strong, it is not necessarily significant. Thus,
a p-value evaluating the significance of the correlation can be estimated by first
calculating a t-value defined as:
t = rs
√
n− 2
1− r2s
, (16)
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3.5.1 Time trends
First, the time trends of all the features were analyzed by dividing all of the records
into 2.5 min long epochs and calculating the features for each epoch. As the record-
ings could not be divided evenly in to 2.5 min epochs, the excess data at the start
of the predrug recordings and at the end of the postdrug recordings was cut. From
the feature values of each subject for every montage and frequency band, a mean
was calculated to measure the time trend of the feature in question. These means of
each epoch were then plotted as a function of time to visualize the dynamics of the
features over time. Additionally, to provide a more robust estimation of the time
trends, means for 10 min epochs with 50% overlap were calculated as a mean of
four subsequent 2.5 min epochs. For features that used separate frequency bands,
the low frequency artifact masks were applied for frequency bands that included fre-
quencies from 0.15 Hz to 0.5 Hz. If the low frequency artifact mask indicated that
an epoch contained more than 10% of artifacts, the whole epoch was rejected. The
high frequency masks were applied in the same manner as the low frequency masks,
when the frequency band included frequencies from 15 Hz to 25 Hz. For features
that did not use specific frequency bands, both the low and high frequency masks
were applied. For artifacts detected with the amplitude-based detector, the same
threshold of 10% per epoch was used. If the 2.5 min epoch contained more than 15
seconds of artifacts, the whole epoch was rejected. The calculated time trends were
then plotted and inspected visually to detect clear prominent changes in the feature
values after the patients had received the drug.
3.5.2 Short-term effects
In addition to studying the effects of dexmedetomidine from the complete recordings,
the short-term effects were also examined. In this study the feature values of a 10
min epoch after the patients received the drug were compared to a baseline value
that was calculated from a 12 min epoch before the drug. The 10 min epoch will be
referred as DX and the baseline epoch as BL from here on.
Originally the BL had a length of 10 min as well. However, as some of the
predrug recordings had an excessive amount of artifacts, prolonging BL to 12 min
increased the number of feature values that were able to be computed. Making the
baseline epoch longer than 12 min did not increase the number of feature values
obtained when compared to the 12 min epoch. Both the DX and BL had a one min
margin from the point when the patients received the drug.
From these epochs, artifacts were first removed and then the remaining data
concatenated. The artifact free signals were then cut down into 2.5 min long win-
dows, for which the features were calculated. As the maximum number of windows
for the baseline and the DX epoch was 4, a median was used to calculate a single
value both of the epochs. If there were less than two and a half min remaining of
the data, the feature was ignored. These results were then compared with Wilcoxon
signed-rank test. An example of the comparison between DX and BL values can be
seen in Figure 15.
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Figure 15: An example illustration of pre- and postdrug values of the interquartile range
of aEEG in channel F4. The red line within the boxes represents the mean value of the
pre- or postdrug group. P-value in the title is for Wilcoxon signed-rank test.
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As it could be hypothesized that the expression of the drug effect in EEG could
be dependant on the state of EEG when the subject received the drug, another study
with the BL and DX values was conducted. In other words, the predrug value of the
feature could have an effect on how the feature value changes as the drug is given.
We studied this relationship by making a scatter plot of the absolute change against
the BL value. The change between the post- and predrug values will be addressed as
delta values from here on. A Spearman’s correlation coefficient was then calculated
for these two groups, delta and baseline values, to access the correlation between
them. The delta values of wPLI in channel F3–F4 and frequency band from 8 to
15 Hz are plotted against the baseline value as an example in Figure 16a. Another
way to present this correlation between the delta and the baseline values can be seen
in Figure 16b.
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(a) Example plot of how the correlations were ana-
lyzed and plotted in this study.
Predrug Postdrug
0
0.01
0.02
0.03
0.04
0.05
0.06
0.07
Fe
at
ur
e 
va
lu
e
wPLI, 8 - 15 Hz, F3 - F4
(b) An alternative representa-
tion, where the negative correla-
tion could be interpreted.
Figure 16: Correlation between the delta and baseline values of wPLI channel F3–F4 in
frequencies from 8 to 15 Hz. (a) scatter plot of the deltas and baseline values (b) Pre- and
postdrug values, where the values of the same subject are connected with a line. In both
figures, an outlier subject whose feature value actually increased is highlighted in red. The
correlation coefficient was −0.580 with the p-value being smaller than 0.000.
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3.5.3 Clinical factors
As the baseline value could impact the postdrug value of the same feature, we chose
to study several factors possibly affecting the baseline value. The three different
factors studied were fentanyl, given to a part of the subjects, conceptional age and
background diagnosis. If these factors affected the baseline, it could possibly fade
out the effects of dexmedetomidine and alter the results found.
Fentanyl is a drug used for anesthesia or analgesia that affects the central ner-
vous system and could possibly have an effect on EEG as well. Out of all of the
21 subjects, 12 had received fentanyl. The effect of fentanyl on the baseline was
analyzed with Wilcoxon’s rank sum test to find out if there were differences in the
baseline values between the subjects that had received the drug and the ones that
had not. An example boxplot where fentanyls effect on nestedness coefficient is
plotted, can be seen in Figure 17.
Figure 17: An example illustration of the effect of fentanyl on the baseline value of
nestedness coefficient in 3–8 Hz frequency band for each montage.
The second factor, conceptional age, is the age of the neonate calculated from
conception. As stated previously, the conceptional ages of the subjects ranged from
197 up to 306 days. Due to the rapid development of neonatal brain, conceptional
age could be hypothesized to correlate with at least some of the features used in
the studies. For assessing the correlation between the conceptional age and the
baseline, Spearman’s correlation test was used. In Figure 18, example scatter plots
on conceptional ages effect on ASI are presented.
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Figure 18: An example illustration of conceptional ages effect on ASI of the baseline for
each montage. Figure shows individual subjects as circles and a least squares line. As can
be seen, conceptional age does not show correlations with ASI in these two montages. In
the title CC stands for correlation coefficient.
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The background diagnoses consisted of four different categories, based on their
main diagnoses. These groups were:
0 = other
1 = mild or moderate HIE
2 = severe HIE
3 = myocardial infarction or intraventricular hemorrhage
HIE is brain damage caused by the loss of oxygen or deprivation of blood circu-
lation. This in turn can affect the cortical activity of the neonates. Five subjects
were diagnosed into group 0, while groups 1 and 2 had eight and six subjects, in
respective. Only two subjects were assigned into group 3. The last factor was exam-
ined with Kruskal-Wallis test to find out whether the groups of baseline values come
from the same distribution or not. Examples boxplots of the background diagnosis
affecting the baseline are shown in 19.
Figure 19: An example illustration of the severity of the diagnosis effect on the baseline
value of nestedness in 15–30 Hz frequency bin for channels F3 and F4. Diagnoses are
plotted in different boxplots.
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4 Results
The results for the different studies introduced previously are presented in this sec-
tion. In addition, correlations between different features are assessed at the end of
this section. As the number of feature vectors and studies were large, only signifi-
cant results and examples are presented and all of the gathered results for statistical
tests can be found in the tables of Appendix A.
4.1 Time trends
The total number of time trends plotted in this study was 125, with all of the
different frequency bands and channels listed in Table 1. All of the time trends
were evaluated visually with the emphasis being on clear systematic changes in the
postdrug feature values, such as notable increases or decreases.
None of the time trends of features analyzed showed any clear changes. Some
minor fluctuations were apparent in most of the features, however, the fluctuation
did not seem to either increase or decrease after the subjects had received the drug.
On the contrary, the fluctuations were rather arbitrary through out the recordings
in these cases. An example of time trend plot of ASI is presented in Figure 20.
However, it should be noted that for illustration only the 200 minutes around the
dexmedetomidine dosing is shown. For the visual analysis the whole length of 480
minutes, for most subjects, was used.
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Figure 20: Time trend of ASI for channel F3P3–F4P4. In the figure, subjects are plotted
in grey while the red plot is the mean of 10 minute epochs of all subjects. As can be clearly
seen from the figure, the mean values showed no clear effects of dexmedetomidine.
4.2 Short-term effects
The second study was about the short-term effects of dexmedetomidine. As pre-
viously mentioned, this study included the Wilcoxon signed-rank test between the
values before and after the administration of the drug. Another part of this study
was the computation of Spearman’s rank correlation between the delta and the base-
line values. Compared to the time trends study, two additional features were added
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for assessing the short-term effets. The features added were the MFDFA measures
and lower index of rEEG.
ASI: No significant differences between the pre- and postdrug values for ASI.
However, the changes in the values of ASI had significant correlations with the delta
and baseline values as the bipolar montage pair F3P3–F4P4 and both the F4–P4
and F3–F4 had a p-value less than 0.05. All of these correlations were negative, with
correlation coefficients of −0.753 for F3P3–F4P4, −0.548 for F4–P4 and −0.496 for
F3–F4. This means that the greater the value of ASI before the drug, the greater
the decrease after the drug was received. The correlation between delta and baseline
values in F3P3–F4P4 can be seen from a scatter plot presented in Figure 21c.
wPLI: With wPLI, only F3–F4 in a frequency bin from 8 Hz to 15 Hz had a
significant difference between the pre- and postdrug values. However, 9 out of 16
from all frequency bins and channel pairs had significant correlations between the
delta and baseline values. The channel pair F3–P3 showed significant correlations
in both frequency ranges of 0.25–3 Hz and 3–8 Hz. For F4–P4 the frequency ranges
that had significant correlations were 8–15 Hz and 15–30 Hz. The third channel
pair, F3–F4, had significant correlations in 0.25–3 Hz, 3–8 Hz and 8–15 Hz ranges.
The posterior channel pair P3–P4 showed significant correlations in frequencies from
3 to 8 Hz and 15 to 30 Hz. Moreover, as with ASI, they all had strong negative
correlations, with the correlation coefficients ranging from −0.462 to −0.839. A few
examples of significant correlations between the delta and baseline values of wPLI
can be seen in Figures 21a and 21b.
NC: Nestedness did not show any significant differences between the comparison
of postdrug and BL values. This means that the null hypothesis of the Wilcoxon
signed-rank test held in all of the frequency bin and channel combinations. On the
other hand, the delta and baseline values in channel F4 had a significant negative
correlation across all frequency bins. The Spearman’s rank correlation coefficients
for these correlations were from −0.46 to −0.746.
PSD & cPSD: The spectral density measures, PSD and cPSD, had only a few
significant correlations between the feature delta and baseline values. The strong
significant correlations for PSD were in channel F3F4 with a frequency bin from
1 Hz to 3 Hz, as well as channels F3F4, F3 and F4 in a frequency range of 8–
15 Hz. For cPSD, most of the significant correlations were in the same frequency
bin as with PSD, from 8 to 15 Hz. In this frequency bin, channel pairs that had
significant correlations were F3P3–F4P4, F3–P3 and F3–F4. In addition, channel
pair F3–F4 showed significant correlation in frequency range of 3–8 Hz. As with
all of the previous features, all of these correlations were strongly negative with
correlation coefficients ranging from −0.492 to −0.729. In the comparison between
the post and predrug values, PSD had no significant results and cPSD had only one.
The only significant difference in the pre- and postdrug values with cPSD was the
negative correlation, correlation coefficient of −0.367, in the channel pair F4–P4 in
a frequency range of 1–3 Hz.
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Figure 21: Scatter plots of delta and baseline values of wPLI montages P3–P4 in 3–8 Hz
(a) and F3–F4 in 8–15 Hz (b). Also a significant correlation in ASI montage F3P3–F4P4
is shown in (c).
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aEEG: Out of the two aEEG measures, mean and IQR, only the postdrug values
of IQR in channel F4 differed significantly from the predrug values. The p-value for
Wilcoxon signed-rank test in this channel was 0.033. For correlations between the
delta and baseline values, neither mean or IQR showed significant correlations.
rEEG: As with aEEG, the rEEG measures had only a few significant results.
These results were the strong negative correlations between the delta and baseline
values with the mean of rEEG in channels F3 and P4. Both the IQR as well as the
lower index, had neither significant correlations with delta and baseline or differences
in the pre- and postdrug distributions of the measure values. Figure 22 shows the
scatter plots of rEEG mean values in channels P3P4, F3 and F4. In addition, scatter
plot of delta and baseline values in channel F3 of rEEG LI is presented in Figure
25b.
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Figure 22: Scatter plots of rEEG mean values in channels (a)P3P4, (b) F3 and (c) F4.
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MFDFA: The last four measures were the peak hq, width hq, tail Dq and height
Dq of MFDFA. Only width hq and tail Dq had significant differences between the
delta and baseline values. Moreover, both of these measures had significant differ-
ences only within one channel. These channels were F3F4 for width hq and P3P4
for tail Dq. However, both width hq and height Dq showed strong significant corre-
lations between the delta and the baseline values, and as with the previous features,
they were all negative with correlation coefficients ranging from −0.486 to −0.728.
The channels that showed correlations for width hq were F3P3, F3, P3 and P4.
For height Dq, channels F3F4 and F4 were the only channels that did not show
significant correlations. Tail Dq had significant correlations in P3P4 and F3 with
the coefficients of −0.566 and −0.565, in respective. Peak hq showed no significant
correlations between the delta and baseline values.
4.3 Clinical factors
For verifying that the results found in the previous studies were indeed a result of
dexmedetomidine, various factors that could affect the baseline values were exam-
ined. As explained in the methods, the examined factors were whether the subjects
had received fentanyl or not, conceptional age and the background diagnosis. The
effect of baseline factors were studied with the same features that were used for
determining the short-term effects.
ASI: Overall, the listed factors did not affect the baseline values of ASI, with
the only exception being a significant difference between the baseline values with
subjects that had received fentanyl and with subject that had not. This difference
was in channel pair F3P3–F4P4. The channel pair in question also had the strongest
negative correlation between delta and baseline values. Figure 23 shows the corre-
lation between delta and baseline values of ASI in this channel, where the fentanyl
groups are plotted differently.
wPLI: As with ASI, there was only one significant effect of fentanyl in wPLI. The
channel pair that had a significant difference in the fentanyl and non-fentanyl values
was F3–P3 in the frequency range of 3–8 Hz. The channel in question also had a
strong correlation between delta and baseline values in the same frequency range.
In Figure 24 this correlation is presented with fentanyl groups. Conceptional age
showed significant correlation also in one channel pair. The channel pair in question
was F3–F4 in frequency range of 0.25–3 Hz and had a correlation coefficient of 0.577.
The different background diagnoses showed no effect on the baseline values of wPLI.
NC, PSD, cPSD, aEEG & rEEG: The baseline factors had no significant effects
for nestedness coefficient, PSD, cPSD or any of the aEEG and rEEG measures, with
the only exception being the channel F3 with rEEG LI. The rEEG LI values in F3
had a strong positive correlation with the baseline value and conceptional age of
the subject. Although not significant with p-values greater than 0.05, channel F4 of
rEEG LI had p-values close to 0.05 in both the delta and baseline study as well as
fentanyl study. This is shown in Figure 25a.
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Figure 23: Correlations between the delta and baseline values of ASI in channel pair
F3P3–F4P4. Subjects who had received fentanyl are plotted in red circles, while the black
squares represent subjects without fentanyl. For illustrating the correlation, a least square
fit was plotted in blue. The Spearman’s rank correlation coefficient was −0.75 and the
respective p-value = 0.001. The values of subjects with and without fentanyl have clearly
grouped into distinct groups, as the p-value of 0.023 for Wilcoxon rank-sum test would
suggest.
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Figure 24: Correlations between the delta and baseline values of wPLI in channel pair
F3–P3. Subjects who had received fentanyl are plotted in red circles, while the black
squares represent subjects without fentanyl. For illustrating the correlation, a least square
fit was plotted in blue. The Spearman’s rank correlation coefficient was −0.84 and the
respective p-value = 0.0001. The corresponding p-value of Wilcoxon rank-sum test for
determining the effect of fentanyl was 0.049.
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Figure 25: Scatter plots of rEEG LI values in channels (a) F4 and (b) F3. Correlations
between the delta and baseline values of rEEG LI in channel F4. In (a), subjects who
had received fentanyl are plotted in red circles, while the black squares represent subjects
without fentanyl. For illustrating the correlation, a least square fit was plotted in blue to
both figures. Although, neither had a p-value less than 0.05, they were both close to the
confidence level.
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MFDFA: Out of all of the MFDFA measures, only one showed any effect of
fentanyl on the baseline value. The effect of fentanyl was expressed in channel P3
with height Dq. On the other hand, conceptional age showed significant correlations
in most of the channels with peak hq. The only channels not having a significant
correlation were P3P4 and F4. In addition, the baseline values of width hq in channel
F4 showed significant correlations with conceptional age. Width hq channel F3 was
the only measure to show any significant differences in the feature values between
the groups with different background diagnoses, out of all the calculated features in
any frequency bin and channel.
4.4 Correlations between ASI, wPLI and cPSD
In this thesis the correlations between ASI, wPLI and cPSD were also examined to
study if there is dependencies between them. These features were chosen as they are
all measures that are calculated between pairs of channels. Correlations between the
postdrug values of the features are presented in Figure 26, while Figure 27 shows
the correlations between the changes in the values after the patients had received
dexmedetomidine.
In the figures, the color of each cell represents the Spearman’s rank correlation
coefficient between two variables, rows and columns. Positive correlations are shown
in red, while negative correlations are in blue. If the correlation between the two
variables was either insignificant, p-value > 0.05, or the correlation was not strong
enough, absolute value of the efficient < 0.2, the correlation is shown in white.
As can be seen in Figure 26 the postdrug values of ASI and cPSD show positive
correlations between them, especially the ASI of F4–P4 and the values of cPSD
in the frequency bins of 3–8 Hz and 8–15 Hz. However, there seems to be neither
positive or negative correlation between ASI and wPLI in any frequency bin. Almost
all of the strong correlations between cPSD and wPLI are negative, although there
are only a few. The variables of cPSD have the strongest correlations with each
other compared to the variables of ASI or wPLI.
With the delta values of ASI, cPSD and wPLI, there seems to be less strong
correlations when compared to the strong correlations between the postdrug val-
ues. However, between wPLI and cPSD, there can be seen both a few negative
correlations as well as a few positive ones.
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5 Discussion
The studies carried out in this thesis provide evidence that dexmedetomidine does
affect the cortical activity of neonates. They also indicate that the effects take place
shortly after the dosing of the drug. The results gathered in the studies are discussed
below.
5.1 Differences between features and studies
The lack of results found in the time trends clearly would indicate that dexmedeto-
midine does not at least have any strong effects that would be clearly seen in the
EEG, such as completely wipe out synchronies found with in the brain, such as
phase-phase synchrony. However, this could also be due to the different background
state of the subjects that supposedly was the cause of the arbitrary time trends even
before dexmedetomidine.
The most significant results were found in the short-term studies, as there were
multiple strong correlations between the baseline and the change of feature value
after the drug. These correlations indicate that dexmedetomidine does affect the
cortical activity of the subjects. Although there were a few strong correlations
between the post- and predrug values aswell, they are negligible as no post hoc
correction was performed.
Most of the significant correlations in short-term studies were found with fea-
tures that measure synchrony between two regions in the brain: ASI and wPLI.
Interestingly, they were all negative, meaning that the greater the baseline value
of a feature, the greater the decrease or smaller the increase in the value after the
patients received the drug. However, when comparing whether feature value in the
pre- or postdrug epoch was greater, no clear consensus was found. Moreover, the
effect on synchrony did not seem to be dependant on the region of the brain, as
significant correlations were found within all channel pairs of wPLI.
As the correlation between ASI and wPLI was also examined and found not to
exist. It can be stated that the significant results of either ASI or wPLI are not
dependant on the other. Interestingly none of the ASI, wPLI and cPSD seemed
to correlate with each other to a meaningful amount. Also, the different montages
within the features seemed to correlate more with the postdrug values than delta
values.
As presented in the results, only the MFDFA peak hq values expressed correlation
with the studied clinical factors in any meaningful amount. However, the feature
did not show any correlations with dexmedetomidine. The lack of any correlations
in short-term studies could be due to the effect of conceptional age that conceals
the effects of dexmedetomidine. Especially as the other variables of MFDFA showed
correlations in short-term studies to an extent, especially the width hq and height
Dq. Moreover, neither of these variables expressed correlations with the clinical
factors.
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Previously dexmedetomidine has been reported to induce brain activity resem-
bling stage II sleep [28, 65]. Mason et al. [65] also found out that dexmedetomidine
sedation resulted in increased activity in theta, alpha and beta frequency bands.
However, as PSD had only a few significant correlations in the frequencies from 8
to 15 Hz, the sleep like induced sedation of dexmedetomidine cannot be confirmed
with our findings. This could be due to the neonates being critically ill and heavily
medicated, and thus it is questionable if they would express any sleep stages at all
even one induced by medication.
5.2 Technical limitations and strengths
The presence of artifacts proved to be the most challenging technical limitation
for our study, as is often the case with EEG studies. For some studies, choosing
manually artifact free epochs is suitable, however, for us it was not possible as we
had to take into account either the time until or from the moment the subjects
received the drug. This was necessary for the data from different subjects to be
comparable in both for the time trends as well as the short-term effects.
Another challenge with the study was the different clinical backgrounds between
the subjects. As all of the newborns were critically ill, obtaining a homogeneous
study group with similar clinical background, i.e. diagnoses and medication, was
not possible. And thus, the differing clinical backgrounds could affect the cortical
activity of the subjects and the results obtained in this study. Furthermore, as
we hypothesized fentanyl could have affected the lack of results found even though
most of the features did not express correlation with the patients receiving fentanyl.
However, as only the exact time for receiving dexmedetomidine was known and
not when the neonates received fentanyl, it could be possible that the some of the
subjects received it hours after dexmedetomidine. Thus, the groups of subjects used
for studying the effects of fentanyl on the baseline value might have been inaccurate,
as we only examined the preceding 12 minutes of dexmedetomidine dosing. On the
other hand, Chrysostomou et al. also studied sedation induced by dexmedetomidine
and found out that fentanyl does not affect the sedation. [66] Their study subjects
included neonates, although did not consist of them exclusively.
One additional limitation caused by the differences between the subjects could be
because of the huge variability in conceptional ages of the subjects. The difference in
conceptional age between the youngest and the oldest neonate was almost 16 weeks,
which is a very long time in the early development of the neonatal brain. Thus the
different developmental state of the brain could result in different expressions of the
medication.
The most significant technical strength in this study was the chosen feature set.
The chosen features measure the cortical activity extensively and versatilely. In
addition, the stability of the features used in this study, with the exception of aEEG
and rEEG, was studied previously by Julia Jaatela [7]. In her thesis, Jaatela showed
that the values of these features do not vary significantly between different epochs
and epoch lengths meaning that they are stable over time.
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Another strength in the studies conducted, was taking into account various dif-
ferent factors that could affect either the baseline value of the subject, or alter the
effect of dexmedetomidine.
5.3 Future prospects
As the effects of dexmedetomidine were left somewhat unclear, other than the fact
that they are found shortly after the patients received the drug and affected the
synchrony in the brain, more research on the matter needs to be conducted. In ad-
dition, repeating the short-term studies with differing time passed since the subjects
received dexmedetomidine could be of interest. For example studying epochs from
10 to 20 and from 20 to 30 minutes after the dosing and comparing them to the
baseline could provide some new information.
One of the implications provided by the results presented in this thesis is that
hour-long recordings of EEG are not necessary for future studies of dexmedetomi-
dine. In addition, the results suggest that dexmedetomidine could affect mainly
the synchrony of the brain and thus focusing on features that measure correlations
between two regions of the brain could be of interest.
For future studies, focusing on the measurement setup in order to prevent un-
necessary artifacts would be a major improvement. This is challenging, however, as
the subjects are neonates and controlling them, for example their movements, while
doing the measurements is difficult. It could also be argued that a larger sample
size than 21 subjects would provide more reliable results.
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6 Conclusions
The goal of this thesis was to study whether dexmedetomidine would affect the
cortical activity of neonates or not. The effects were studied on different time scales
and various different factors that could affect the results were analyzed as presented
in the beginning of this thesis. The computational features used in these studies
were statistically analyzed for consistent differences between the distributions of pre
and postdrug values.
No conclusions on the hour-long lasting effects of dexmedetomidine were able to
be deducted based on the time trends and thus dexmedetomidine does not seem to
have effects that would last that long. The lack of these kind of results were also
speculated to be a result of the critical illness and the different background states
of the neonates due to varying medical conditions.
However, in the short-term studies, dexmedetomidine was clearly shown to have
an effect on the synchrony within the brain as both ASI and wPLI had significant
results. The correlation between these features was also studied and they were shown
not to be dependant on each other. Due to the scarce nature of the results and the
effects being expressed on different channels and frequencies, no conclusions were
able to be made on either the location or the frequencies that dexmedetomidine
would specifically affect.
In the last study of different clinical factors effect on the baseline values of the
neonates, it was shown that they did not have an effect. Thus the results presented
in this thesis can be considered reliable and truthful.
This thesis can be used as preparatory groundwork for following studies as it was
shown that hour-long recordings of EEG do not seem to be needed for examining
the effects of dexmedetomidine. However, further research is required to confirm
these findings.
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A Appendix A
In this appendix, the results of all of the features are listed in their own tables and
the feature in question is specified in the label. Results for different frequency and
channel combinations are presented in their own rows. The second column the p-
value for Wilcoxon signed-rank test between the postdrug and predrug values are
listed. In the next column (DX/BL ↑), the epoch that had the greater feature value
is stated, BL = baseline and DX = postdrug. The correlation coefficient (∆/BL
(rho)) and p-value (∆/BL (p-value)) for Spearman’s rank correlation between the
delta values and baseline values are given in the following two columns. In the
Fentanyl-column the p-values for Wilcoxon’s rank sum tests are listed. While the
CA labeled columns consist of the correlation coefficient (rho) and p-value for Spear-
man’s correlation tests between the conceptional age and baseline values. In the last
column in the tables are listed the p-values of Kruskal-Wallis test for different back-
ground diagnoses. In the tables, p-values of less than 0.05 are highlighted in red
while values of 0.10 > p-value > 0.05 are highlighted in green.
Table A1: ASI
Channel:
DX/BL
(p-value)
DX/BL
↑
∆/BL
(rho)
∆/BL
(p-value)
Fentanyl
(p-value)
CA
(rho)
CA
(p-value)
Diagnosis
(p-value)
F3P3 — F4P4 0.569 BL -0.753 0.001 0.023 0.397 0.128 0.500
F3 — P3 0.936 BL -0.214 0.377 0.837 -0.068 0.783 0.324
F4 — P4 0.064 DX -0.548 0.020 0.173 0.030 0.906 0.993
F3 — F4 0.446 BL -0.496 0.038 0.930 0.099 0.696 0.212
P3 — P4 0.126 DX -0.160 0.512 0.206 0.262 0.279 0.407
Table A2: wPLI
Frequency band: Channel:
DX/BL
(p-value)
DX/BL
↑
∆/BL
(rho)
∆/BL
(p-value)
Fentanyl
(p-value)
CA
(rho)
CA
(p-value)
Diagnosis
(p-value)
0.25 — 3 Hz F3 — P3 0.778 DX -0.593 0.005 0.152 0.204 0.403 0.698
0.25 — 3 Hz F4 — P4 0.948 BL -0.408 0.072 0.600 0.255 0.293 0.318
0.25 — 3 Hz F3 — F4 0.823 DX -0.719 0.000 0.298 0.577 0.008 0.939
0.25 — 3 Hz P3 — P4 0.687 BL -0.444 0.111 0.965 -0.170 0.499 0.763
3 — 8 Hz F3— P3 0.263 BL -0.839 0.000 0.049 -0.350 0.130 0.332
3 — 8 Hz F4 — P4 0.494 DX -0.412 0.195 0.840 -0.004 0.986 0.740
3 — 8 Hz F3 — F4 0.911 DX -0.462 0.011 0.418 0.114 0.631 0.162
3 — 8 Hz P3 — P4 0.573 DX -0.753 0.000 0.968 -0.031 0.901 0.734
8 — 15 Hz F3 — P3 0.411 BL -0.835 0.054 0.671 -0.259 0.270 0.481
8 — 15 Hz F4 — P4 0.126 BL -0.733 0.001 0.442 0.186 0.445 0.670
8 — 15 Hz F3 — F4 0.044 BL -0.580 0.000 0.114 0.004 0.987 0.784
8 — 15 Hz P3 — P4 0.184 DX -0.728 0.662 0.717 -0.204 0.403 0.231
15 — 30 Hz F3 — P3 0.243 DX -0.826 0.743 0.536 -0.083 0.734 0.268
15 — 30 Hz F4— P4 0.420 BL -0.709 0.013 0.965 0.165 0.512 0.109
15 — 30 Hz F3 — F4 0.845 DX -0.763 0.056 0.536 -0.066 0.794 0.337
15 — 30 Hz P3 — P4 0.936 DX -0.537 0.049 0.310 -0.143 0.559 0.690
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Table A3: NC
Frequency band: Channel:
DX/BL
(p-value)
DX/BL
↑
∆/BL
(rho)
∆/BL
(p-value)
Fentanyl
(p-value)
CA
(rho)
CA
(p-value)
Diagnosis
(p-value)
3 — 8 Hz F3 0.062 BL -0.050 0.836 0.375 0.315 0.177 0.275
3 — 8 Hz F4 0.550 DX -0.460 0.043 0.728 0.383 0.096 0.620
3 — 8 Hz P3 0.167 DX -0.429 0.061 0.908 -0.092 0.700 0.814
3 — 8 Hz P4 0.084 DX -0.449 0.055 0.717 -0.262 0.279 0.523
8 — 15 Hz F3 0.794 DX -0.302 0.195 0.059 0.443 0.050 0.107
8 — 15 Hz F4 0.654 BL -0.746 0.000 0.908 0.246 0.296 0.090
8 — 15 Hz P3 0.433 DX -0.295 0.207 0.335 -0.138 0.560 0.447
8 — 15 Hz P4 0.872 DX -0.232 0.339 0.778 0.005 0.983 0.959
15 — 30 Hz F3 0.904 BL -0.218 0.369 0.773 -0.323 0.177 0.854
15 — 30 Hz F4 0.546 DX -0.519 0.024 0.717 0.111 0.652 0.080
15 — 30 Hz P3 0.778 BL -0.228 0.346 0.657 -0.020 0.935 0.681
15 — 30 Hz P4 0.215 DX -0.251 0.314 0.904 0.223 0.359 0.574
Table A4: PSD
Frequency band: Channel:
DX/BL
(p-value)
DX/BL
↑
∆/BL
(rho)
∆/BL
(p-value)
Fentanyl
(p-value)
CA
(rho)
CA
(p-value)
Diagnosis
(p-value)
1 — 3 Hz F3P3 0.627 BL -0.310 0.183 0.787 0.123 0.606 0.344
1 — 3 Hz F4P4 0.809 BL -0.186 0.444 0.442 0.024 0.923 0.486
1 — 3 Hz F3F4 0.218 BL -0.632 0.003 0.232 0.201 0.396 0.164
1 — 3 Hz P3P4 0.629 BL -0.442 0.060 0.717 -0.087 0.723 0.562
1 — 3 Hz F3 0.411 BL -0.296 0.204 0.671 0.090 0.705 0.507
1 — 3 Hz F4 0.455 BL -0.392 0.088 0.203 0.083 0.729 0.390
1 — 3 Hz P3 1.000 DX -0.292 0.211 0.969 -0.012 0.960 0.995
1 — 3 Hz P4 0.872 DX -0.356 0.135 0.778 -0.106 0.665 0.681
3 — 8 Hz F3P3 0.970 DX -0.155 0.513 0.908 0.035 0.885 0.949
3 — 8 Hz F4P4 0.717 BL -0.039 0.877 1.000 -0.075 0.761 0.870
3 — 8 Hz F3F4 0.601 BL -0.030 0.901 0.563 0.152 0.522 0.731
3 — 8 Hz P3P4 0.546 BL -0.021 0.934 0.840 -0.208 0.393 0.892
3 — 8 Hz F3 0.911 BL -0.335 0.148 0.787 0.087 0.717 0.588
3 — 8 Hz F4 0.654 BL -0.286 0.221 0.512 0.132 0.578 0.731
3 — 8 Hz P3 0.737 DX -0.090 0.705 0.847 -0.029 0.905 0.994
3 — 8 Hz P4 1.000 BL -0.344 0.150 0.717 -0.220 0.365 0.930
8 — 15 Hz F3P3 0.263 BL -0.171 0.468 1.000 -0.034 0.887 0.962
8 — 15 Hz F4P4 0.748 BL -0.167 0.494 0.778 -0.043 0.861 0.876
8 — 15 Hz F3F4 0.156 BL -0.528 0.018 0.787 -0.023 0.925 0.584
8 — 15 Hz P3P4 0.421 BL 0.074 0.765 0.968 -0.295 0.220 0.931
8 — 15 Hz F3 0.296 DX -0.493 0.029 0.847 -0.045 0.850 0.840
8 — 15 Hz F4 0.313 BL -0.678 0.001 0.512 0.061 0.799 0.653
8 — 15 Hz P3 0.881 BL -0.135 0.568 0.728 -0.203 0.390 0.964
8 — 15 Hz P4 0.904 BL -0.247 0.306 0.717 -0.296 0.219 0.942
15 — 30 Hz F3P3 0.573 DX -0.209 0.389 0.650 0.107 0.663 0.440
15 — 30 Hz F4P4 0.845 BL -0.447 0.065 0.460 -0.053 0.836 0.901
15 — 30 Hz F3F4 0.913 BL -0.185 0.462 1.000 -0.027 0.916 0.182
15 — 30 Hz P3P4 0.968 BL -0.211 0.385 0.717 -0.289 0.230 0.986
15 — 30 Hz F3 0.936 BL -0.158 0.517 1.000 0.084 0.732 0.417
15 — 30 Hz F4 0.573 BL -0.309 0.198 0.310 0.118 0.631 0.443
15 — 30 Hz P3 0.970 BL -0.132 0.577 0.728 -0.080 0.738 0.933
15 — 30 Hz P4 0.573 DX -0.335 0.161 0.904 -0.274 0.256 0.940
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Table A5: cPSD
Frequency band: Channel:
DX/BL
(p-value)
DX/BL
↑
∆/BL
(rho)
∆/BL
(p-value)
Fentanyl
(p-value)
CA
(rho)
CA
(p-value)
Diagnosis
(p-value)
1 — 3 Hz F3P3 — F4P4 0.948 DX -0.393 0.107 0.829 -0.120 0.636 0.529
1 — 3 Hz F3 — P3 0.881 BL -0.445 0.051 0.375 0.040 0.867 0.493
1 — 3 Hz F4 — P4 0.049 BL -0.367 0.123 0.968 -0.039 0.875 0.628
1 — 3 Hz F3 — F4 0.313 DX 0.032 0.896 0.969 -0.093 0.698 0.448
1 — 3 Hz P3 — P4 0.841 DX -0.354 0.137 0.717 0.261 0.281 0.482
3 — 8 Hz F3P3 — F4P4 0.647 BL -0.333 0.176 0.829 -0.134 0.595 0.862
3 — 8 Hz F3 — P3 1.000 BL -0.153 0.517 0.616 0.284 0.224 0.802
3 — 8 Hz F4 — P4 0.687 DX -0.193 0.427 0.968 0.083 0.737 0.945
3 — 8 Hz F3 — F4 0.279 DX -0.729 0.000 0.908 0.027 0.910 0.655
3 — 8 Hz P3 — P4 0.936 BL -0.195 0.423 0.657 -0.130 0.596 0.906
8 — 15 Hz F3P3 — F4P4 0.094 BL -0.523 0.028 1.000 0.161 0.523 0.512
8 — 15 Hz F3 — P3 0.765 DX -0.577 0.009 0.671 0.041 0.865 0.932
8 — 15 Hz F4 — P4 0.936 BL -0.282 0.240 0.351 -0.238 0.327 0.955
8 — 15 Hz F3 — F4 0.455 DX -0.492 0.029 0.969 0.108 0.649 0.549
8 — 15 Hz P3 — P4 0.904 DX -0.230 0.342 0.395 -0.011 0.966 0.799
15 — 30 Hz F3P3 — F4P4 0.836 BL 0.088 0.746 0.681 -0.175 0.517 0.685
15 — 30 Hz F3 — P3 0.841 DX -0.233 0.335 0.482 -0.066 0.789 0.917
15 — 30 Hz F4 — P4 0.811 BL -0.253 0.310 0.829 -0.209 0.406 0.318
15 — 30 Hz F3 — F4 0.420 DX -0.195 0.436 0.536 -0.118 0.642 0.985
15 — 30 Hz P3 — P4 0.212 DX -0.060 0.809 0.545 -0.136 0.579 0.911
Table A6: aEEG mean
Channel:
DX/BL
(p-value)
DX/BL
↑
∆/BL
(rho)
∆/BL
(p-value)
Fentanyl
(p-value)
CA
(rho)
CA
(p-value)
Diagnosis
(p-value)
F3P3 0.398 DX -0.368 0.121 0.840 0.196 0.422 0.645
F4P4 0.398 BL -0.396 0.094 0.310 0.133 0.586 0.536
F3F4 0.852 BL -0.203 0.389 0.375 0.274 0.243 0.325
P3P4 0.494 BL -0.349 0.143 0.492 -0.093 0.705 0.891
F3 0.881 BL -0.438 0.055 0.512 0.184 0.437 0.696
F4 0.911 DX -0.271 0.247 0.512 0.251 0.285 0.469
P3 0.502 DX -0.110 0.644 1.000 0.014 0.955 0.961
P4 0.687 DX -0.419 0.075 0.840 0.013 0.957 0.726
Table A7: aEEG IQR
Channel:
DX/BL
(p-value)
DX/BL
↑
∆/BL
(rho)
∆/BL
(p-value)
Fentanyl
(p-value)
CA
(rho)
CA
(p-value)
Diagnosis
(p-value)
F3P3 0.227 DX 0.200 0.410 0.968 -0.119 0.626 0.989
F4P4 0.520 DX 0.107 0.662 0.778 -0.169 0.488 0.946
F3F4 0.823 DX -0.174 0.460 0.512 -0.087 0.714 0.794
P3P4 0.841 BL 0.049 0.843 0.968 -0.295 0.220 0.903
F3 0.575 BL -0.081 0.733 0.969 -0.162 0.496 0.866
F4 0.033 BL 0.186 0.429 0.908 -0.115 0.629 0.868
P3 0.073 BL 0.143 0.547 0.847 -0.223 0.344 0.951
P4 0.421 BL -0.204 0.402 0.968 -0.181 0.459 0.753
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Table A8: rEEG mean
Channel:
DX/BL
(p-value)
DX/BL
↑
∆/BL
(rho)
∆/BL
(p-value)
Fentanyl
(p-value)
CA
(rho)
CA
(p-value)
Diagnosis
(p-value)
F3P3 0.748 DX -0.346 0.147 0.902 0.114 0.642 0.529
F4P4 0.744 DX -0.300 0.225 0.360 -0.124 0.624 0.502
F3F4 0.777 BL -0.296 0.232 0.536 0.101 0.690 0.139
P3P4 0.445 BL -0.414 0.079 0.545 -0.104 0.673 0.456
F3 0.421 BL -0.612 0.006 0.711 0.192 0.431 0.409
F4 0.658 DX -0.440 0.061 0.238 0.050 0.839 0.425
P3 0.823 DX -0.205 0.385 0.969 -0.004 0.987 0.986
P4 0.717 DX -0.489 0.035 0.840 -0.093 0.705 0.600
Table A9: rEEG IQR
Channel:
DX/BL
(p-value)
DX/BL
↑
∆/BL
(rho)
∆/BL
(p-value)
Fentanyl
(p-value)
CA
(rho)
CA
(p-value)
Diagnosis
(p-value)
F3P3 0.778 DX -0.128 0.600 0.773 -0.147 0.547 0.796
F4P4 0.811 BL -0.245 0.327 0.573 -0.154 0.542 0.589
F3F4 0.777 BL -0.069 0.786 0.659 -0.239 0.341 0.398
P3P4 0.778 DX -0.291 0.226 1.000 -0.189 0.439 0.666
F3 0.334 DX -0.423 0.073 0.902 -0.090 0.716 0.872
F4 0.748 BL 0.023 0.928 0.395 -0.041 0.867 0.515
P3 0.970 BL 0.047 0.846 1.000 -0.194 0.412 0.826
P4 0.445 BL -0.275 0.253 0.840 -0.162 0.506 0.666
Table A10: rEEG LI
Channel:
DX/BL
(p-value)
DX/BL
↑
∆/BL
(rho)
∆/BL
(p-value)
Fentanyl
(p-value)
CA
(rho)
CA
(p-value)
Diagnosis
(p-value)
F3P3 0.778 BL -0.170 0.485 0.536 0.432 0.065 0.340
F4P4 0.711 BL -0.226 0.366 0.083 0.083 0.744 0.600
F3F4 0.616 DX -0.067 0.792 0.151 0.465 0.052 0.264
P3P4 0.778 BL -0.184 0.449 0.310 0.133 0.586 0.248
F3 0.629 DX -0.447 0.056 0.340 0.528 0.020 0.293
F4 0.968 BL -0.428 0.069 0.091 0.348 0.145 0.314
P3 0.765 BL -0.156 0.509 0.908 0.283 0.227 0.436
P4 0.841 DX -0.349 0.143 0.545 0.056 0.819 0.169
Table A11: MFDFA peak hq
Channel:
DX/BL
(p-value)
DX/BL
↑
∆/BL
(rho)
∆/BL
(p-value)
Fentanyl
(p-value)
CA
(rho)
CA
(p-value)
Diagnosis
(p-value)
F3P3 0.133 DX 0.443 0.067 1.000 -0.515 0.029 0.320
F4P4 0.177 BL -0.044 0.869 0.965 -0.558 0.016 0.279
F3F4 0.064 BL 0.191 0.446 0.596 -0.478 0.045 0.133
P3P4 0.619 DX -0.071 0.787 0.515 -0.386 0.113 0.094
F3 0.778 DX 0.042 0.865 0.650 -0.476 0.040 0.289
F4 0.314 DX 0.346 0.147 0.545 -0.369 0.120 0.470
P3 0.355 BL 0.160 0.512 0.492 -0.460 0.047 0.146
P4 0.071 BL 0.026 0.921 0.600 -0.552 0.014 0.058
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Table A12: MFDFA width hq
Channel:
DX/BL
(p-value)
DX/BL
↑
∆/BL
(rho)
∆/BL
(p-value)
Fentanyl
(p-value)
CA
(rho)
CA
(p-value)
Diagnosis
(p-value)
F3P3 0.811 DX -0.486 0.043 0.860 -0.129 0.610 0.300
F4P4 0.687 BL -0.176 0.497 0.696 -0.269 0.281 0.716
F3F4 0.006 DX -0.397 0.104 0.791 -0.363 0.138 0.139
P3P4 0.981 DX -0.338 0.184 0.633 -0.362 0.140 0.648
F3 0.314 DX -0.488 0.036 0.711 -0.366 0.123 0.044
F4 0.227 BL -0.196 0.418 0.351 -0.481 0.037 0.474
P3 0.658 DX -0.572 0.012 0.600 -0.127 0.604 0.727
P4 0.711 DX -0.575 0.014 0.600 -0.276 0.253 0.834
Table A13: MFDFA tail Dq
Channel:
DX/BL
(p-value)
DX/BL
↑
∆/BL
(rho)
∆/BL
(p-value)
Fentanyl
(p-value)
CA
(rho)
CA
(p-value)
Diagnosis
(p-value)
F3P3 0.184 DX -0.292 0.239 0.596 -0.007 0.977 0.866
F4P4 0.177 DX -0.407 0.106 0.315 -0.080 0.754 0.899
F3F4 0.396 DX -0.383 0.118 0.056 0.320 0.195 0.897
P3P4 0.044 DX -0.566 0.020 0.460 0.020 0.938 0.468
F3 0.904 BL -0.565 0.013 0.837 0.171 0.484 0.340
F4 0.077 BL -0.418 0.077 0.492 0.169 0.490 0.718
P3 0.968 BL -0.193 0.427 0.272 0.137 0.576 0.302
P4 0.349 DX -0.203 0.417 0.657 0.023 0.926 0.398
Table A14: MFDFA height Dq
Channel:
DX/BL
(p-value)
DX/BL
↑
∆/BL
(rho)
∆/BL
(p-value)
Fentanyl
(p-value)
CA
(rho)
CA
(p-value)
Diagnosis
(p-value)
F3P3 0.845 DX -0.624 0.007 0.536 0.034 0.893 0.934
F4P4 0.246 DX -0.632 0.008 0.696 -0.003 0.990 0.964
F3F4 0.112 DX -0.073 0.773 0.069 -0.249 0.319 0.572
P3P4 0.102 BL -0.728 0.001 0.829 -0.083 0.744 0.813
F3 0.494 BL -0.556 0.015 0.432 0.147 0.547 0.097
F4 0.398 DX -0.335 0.161 1.000 -0.291 0.226 0.999
P3 0.184 DX -0.640 0.004 0.020 0.039 0.875 0.838
P4 0.879 DX -0.668 0.003 0.840 -0.002 0.994 0.993
